Journey Medical stock reports Q2 revenue of USD 18.51 million

Published on 10/04/2026 at 23:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Journey Medical stock enters October with Q2 revenue of USD 18.51 million, ahead of the USD 18.36 million consensus estimate. DERM closed at USD 6.61 on October 2, 2026.

DERM, US48115J1097, Illustration mit AI erstellt.

Journey Medical stock (ISIN US48115J1097) closed at USD 6.61 on Nasdaq on October 2, 2026, down 1.64 percent from USD 6.72. The company reported Q2 2026 revenue of USD 18.51 million and a GAAP net loss of USD 312,000, with the quarterly release covered by MarketBeat on October 3, 2026.

Revenue beats the quarterly estimate

Journey Medical's Q2 revenue exceeded the USD 18.36 million consensus estimate by USD 150,000. The result also improved on revenue of USD 15.01 million in Q2 2025, while the GAAP net loss narrowed from USD 3.8 million to USD 312,000, according to Markets Insider on September 22, 2026.

Quarterly EPS was a loss of USD 0.01, compared with the consensus estimate of a USD 0.02 loss. Operating profit was USD 456,000 in Q2 2026, following an operating loss of USD 1.492 million in Q1 2026.

EMROSI drives the growth story

At the H.C. Wainwright conference on September 14, 2026, Journey Medical highlighted EMROSI as its leading growth product in rosacea. Investing.com reported that EMROSI generated 130,000 prescriptions through July 2026 and reached 4,500 unique prescribers. The product recorded more than 35,000 prescriptions in Q2 2026, compared with 27,000 in Q4 2025.

The commercial platform spans acne, rosacea and hyperhidrosis treatments. Journey Medical ended Q2 2026 with USD 25.643 million in cash, while its product portfolio and sales infrastructure remain central to the company's expansion strategy.

Analyst target stays above the share price

MarketBeat reported on October 3, 2026, that four analysts produced a Hold consensus with an average price target of USD 14.00. B. Riley raised its target from USD 12.00 to USD 15.00 on August 13, 2026, while the latest share price stood at USD 6.61.

DERM remains below its yearly high

DERM traded within a 52-week range of USD 4.31 to USD 9.56 as of October 2, 2026. The USD 6.61 close was USD 2.95 below the yearly high, and 126,174 shares changed hands during the session. The stock's market capitalization was USD 186.6 million.